» Articles » PMID: 35955584

Cobra Venom Factor Boosts Arteriogenesis in Mice

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Aug 12
PMID 35955584
Authors
Affiliations
Soon will be listed here.
Abstract

Arteriogenesis, the growth of natural bypass blood vessels, can compensate for the loss of arteries caused by vascular occlusive diseases. Accordingly, it is a major goal to identify the drugs promoting this innate immune system-driven process in patients aiming to save their tissues and life. Here, we studied the impact of the Cobra venom factor (CVF), which is a C3-like complement-activating protein that induces depletion of the complement in the circulation in a murine hind limb model of arteriogenesis. Arteriogenesis was induced in C57BL/6J mice by femoral artery ligation (FAL). The administration of a single dose of CVF (12.5 µg) 24 h prior to FAL significantly enhanced the perfusion recovery 7 days after FAL, as shown by Laser Doppler imaging. Immunofluorescence analyses demonstrated an elevated number of proliferating (BrdU) vascular cells, along with an increased luminal diameter of the grown collateral vessels. Flow cytometric analyses of the blood samples isolated 3 h after FAL revealed an elevated number of neutrophils and platelet-neutrophil aggregates. Giemsa stains displayed augmented mast cell recruitment and activation in the perivascular space of the growing collaterals 8 h after FAL. Seven days after FAL, we found more CD68/MRC-1 M2-like polarized pro-arteriogenic macrophages around growing collaterals. These data indicate that a single dose of CVF boosts arteriogenesis by catalyzing the innate immune reactions, relevant for collateral vessel growth.

Citing Articles

Enhanced complement activation and MAC formation accelerates severe COVID-19.

Ellsworth C, Chen Z, Xiao M, Qian C, Wang C, Shamima Khatun M Cell Mol Life Sci. 2024; 81(1):405.

PMID: 39284944 PMC: 11405604. DOI: 10.1007/s00018-024-05430-w.


The Complement System Is Essential for Arteriogenesis by Enhancing Sterile Inflammation as a Relevant Step in Collateral Artery Growth.

Zhu A, Baur C, Gotz P, Elbs K, Lasch M, Faro A Cells. 2024; 13(17.

PMID: 39272977 PMC: 11394660. DOI: 10.3390/cells13171405.


The Intriguing World of Vascular Remodeling, Angiogenesis, and Arteriogenesis.

Quax P, Deindl E Int J Mol Sci. 2024; 25(12).

PMID: 38928082 PMC: 11204171. DOI: 10.3390/ijms25126376.


Treatment with Cobra Venom Factor Decreases Ischemic Tissue Damage in Mice.

Azubuike-Osu S, Kuhs A, Gotz P, Faro A, Preissner K, Arnholdt C Biomedicines. 2024; 12(2).

PMID: 38397911 PMC: 10886846. DOI: 10.3390/biomedicines12020309.

References
1.
Morgan B, Harris C . Complement therapeutics; history and current progress. Mol Immunol. 2003; 40(2-4):159-70. DOI: 10.1016/s0161-5890(03)00111-1. View

2.
Candinas D, Lesnikoski B, Robson S, Miyatake T, Scesney S, Marsh Jr H . Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival. Transplantation. 1996; 62(3):336-42. DOI: 10.1097/00007890-199608150-00006. View

3.
Yun S, Sim E, Goh R, Park J, Han J . Platelet Activation: The Mechanisms and Potential Biomarkers. Biomed Res Int. 2016; 2016:9060143. PMC: 4925965. DOI: 10.1155/2016/9060143. View

4.
Petroff D, Czerny M, Kolbel T, Melissano G, Lonn L, Haunschild J . Paraplegia prevention in aortic aneurysm repair by thoracoabdominal staging with 'minimally invasive staged segmental artery coil embolisation' (MIS²ACE): trial protocol for a randomised controlled multicentre trial. BMJ Open. 2019; 9(3):e025488. PMC: 6429943. DOI: 10.1136/bmjopen-2018-025488. View

5.
Turner N, Moake J . Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PLoS One. 2013; 8(3):e59372. PMC: 3612042. DOI: 10.1371/journal.pone.0059372. View